Original: Zhang Xuefeng Used His Life to Deliver His Final Lecture

Funeral and public reaction

Zhang Xuefeng (张雪峰), the controversial education influencer and admissions-planning entrepreneur, died suddenly at 41 and his farewell arrangements were pared down, it has been reported that his memorial will accept no wreaths and hold no public remembrance. The viral news of his collapse—reportedly from a heart-origin sudden death while running—has reignited national anxiety about cardiovascular health. Zhang made his name by tapping China’s anxiety-driven education market; now his death has catalyzed a new, broader panic about mortality and prevention. Who among millions of middle‑aged, high‑stress urban workers feels safe today?

Market reaction: a buying spree

It has been reported that since the news broke on March 24, sales and searches for emergency and preventive heart‑health products have surged across Chinese e‑commerce platforms. Portable AEDs (automated external defibrillators), sublingual nitroglycerin, coenzyme Q10, and traditional "rescue" pills saw two‑ to five‑fold jumps in orders; one AED model priced around ¥4,500 reportedly sold out in Beijing. Search interest in CoQ10 rose tenfold and for quick‑acting cardiac pills by 30 times. The stock and device markets also responded: wearables and AI health products—areas where Apple, Huawei (华为), Xiaomi (小米) and domestic device makers are active—have resumed momentum after a lull. Domestic medical suppliers such as Mindray (迈瑞), Yuyue (鱼跃) and Lepu (乐普) are among firms with offerings in the space. China is estimated to have about 3 million AEDs installed, with a market roughly RMB 60 billion; per‑100,000 comparisons remain stark (China ~0.2, US 317, Japan 555).

Medical reality and the limits of tech

Clinicians warn that the public reaction mixes sensible prevention with misplaced faith in “one‑button” tech. Sudden cardiac death (SCD) is real and rising: a study led by researchers at Fuwai Hospital puts China’s crude SCD mortality at about 18.59 per 100,000 in 2021—more than double 2013—disproportionately affecting men and increasingly hitting middle‑aged adults and even younger people. Survival outside hospital remains dismal—often 1–2%—because the rescue window is measured in minutes and bystanders and public AED availability are often inadequate. Wearables and AI can help: single‑lead ECGs, PPG‑based heart‑rate monitoring and emerging AI risk‑scanners can flag problems early, and it has been reported that some experimental systems can auto‑call emergency services after prolonged pulselessness. But limitations are real: PPG measures pulse rather than true cardiac electrical activity and can misread during exercise; single‑lead devices miss some infarcts; false positives and insufficient clinical evidence are concerns. Technology is part of the answer, not a panacea.

The final lesson

Zhang’s death has done what editorials seldom achieve: it has converted abstract public‑health data into a personal urgency, and sales spikes into a debate about prevention, training and system gaps. Will the shock translate into more AEDs in public places, mass CPR training, routine screening, and better integration of wearable data into clinical care? That remains to be seen. For now, his passing has become, understandably and tragically, a final lecture on the fragility of life—and on the limits of gadgets without broader social and medical change.